Results 21 to 30 of about 236,269 (292)
Minimal residual disease in EGFR-mutant non-small-cell lung cancer
Frontiers in Oncology, 2022 Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an effective treatment for EGFR-mutant non-small-cell lung cancer (NSCLC), however most patients invariably relapse after a period of minimal residual ...
Nathan T. Bain +5 more
doaj +1 more source
Haematologica, 2019 Minimal (or ‘measurable’) residual disease in acute lymphoblastic leukemia appears to be a prognostic indicator, with potential value in informing individualized treatment decisions.
Renato Bassan +5 more
doaj +1 more source
Minimal residual disease [PDF]
Current Opinion in Hematology, 1999 Monitoring of residual disease in patients with malignant hematologic disorders has been recognized as an important diagnostic tool for assessment of the response to treatment and the individual risk of relapse. In a number of malignancies, employment of sensitive techniques permitting the identification of tumor cells within a 10(4)-fold or greater ...
openaire +3 more sources
Haematologica, 2012 Background In the present study, the prognostic impact of minimal residual disease during treatment on time to progression and overall survival was analyzed prospectively in patients with mantle cell lymphoma treated on the Cancer and Leukemia Group B ...
Hongtao Liu +10 more
doaj +1 more source
Optimization of the indications for allogeneic stem cell transplantation in Acute Myeloid Leukemia based on interactive diagnostic strategies [PDF]
, 2011 The indications for allogeneic stem cell transplantation (SCT) in Acute Myeloid Leukemia (AML) represent a real challenge due to the clinical and genetic heterogeneity of the disorder.
Hartwig, Maite +5 more
core +1 more source
Haematologica, 2019 Minimal residual disease has emerged as an important prognostic factor for relapse and survival in acute myeloid leukemia. Eradication of minimal residual disease may increase the number of patients with long-term survival; however, to date, strategies ...
Brian Ball, Eytan M. Stein
doaj +1 more source
Liquid biopsies and minimal residual disease in lymphoid malignancies
Frontiers in Oncology, 2023 Minimal residual disease (MRD) assessment using peripheral blood instead of bone marrow aspirate/biopsy specimen or the biopsy of the cancerous infiltrated by lymphoid malignancies is an emerging technique with enormous interest of research and ...
Maroun Bou Zerdan +10 more
doaj +1 more source
FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia [PDF]
, 2004 Length mutations within the FLT3 gene (FLT3-LM) can be found in 23% of acute myeloid leukaemia (AML) and thus are the most frequent mutations in AML. FLT3-LM are highly correlated with AML with normal karyotype and other cytogenetic aberrations of the ...
Kern, Wolfgang +4 more
core +1 more source
Minimal Residual Disease in Myeloma: Are We There Yet? [PDF]
, 2012 Measurement of minimal residual disease is routine in diseases such as chronic myelogenous leukemia, precursor B cell acute lymphoblastic leukemia, and acute promyelocytic leukemia because it provides important prognostic information.
Kassim, Adetola +5 more
core +1 more source
Dynamics of Minimal Residual Disease in Neuroblastoma Patients
Frontiers in Oncology, 2019 Neuroblastoma is a common extracranial solid tumor of neural crest (NC) origin that accounts for up to 15% of all pediatric cancer deaths. The disease arises from a transient population of NC cells that undergo an epithelial-mesenchymal transition (EMT ...
Suguru Uemura +13 more
doaj +1 more source